cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arvinas Inc
6 own
5 watching
Current Price
$46.47
$-0.83
(-1.75%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,294.95M
52-Week High
52-Week High
53.08000
52-Week Low
52-Week Low
13.57000
Average Volume
Average Volume
0.75M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,294.95M
icon52-Week High53.08000
icon52-Week Low13.57000
iconAverage Volume0.75M
iconDividend Yield--
iconP/E Ratio--
What does the Arvinas Inc do?
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has a collaboration with Bayer AG to develop novel proteolysis-targeting chimera candidates for humans and plants. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More
How much money does Arvinas Inc make?
News & Events about Arvinas Inc.
TipRanks Financial Blog
9 months ago
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Arvinas Holding Company (ARVN Research Report) yesterday and set a pri... Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Arvinas Holding Company (ARVN &#8211...
Globe Newswire
10 months ago
Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population NEW HAVEN, Conn., May 05, 2023 (GLOBE ...
PR Newswire
10 months ago
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform...
Ticker Report
10 months ago
Arvinas, Inc. (NASDAQ:ARVN Get Rating) has been given a consensus rating of Moderate Buy by the eighteen brokerages that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The...
Accesswire
11 months ago
Oerth's unique PROTAC® protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the combination of Oerth Bio's specialized expertise designing PROTAC® degraders for agriculture with...
Frequently Asked Questions
Frequently Asked Questions
What is Arvinas Inc share price today?
plus_minus_icon
Can Indians buy Arvinas Inc shares?
plus_minus_icon
How can I buy Arvinas Inc shares from India?
plus_minus_icon
Can Fractional shares of Arvinas Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arvinas Inc stocks?
plus_minus_icon
What is today’s traded volume of Arvinas Inc?
plus_minus_icon
What is today’s market capitalisation of Arvinas Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arvinas Inc?
plus_minus_icon
What percentage is Arvinas Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arvinas Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$46.47
$-0.83
(-1.75%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00